NCT00276523View on ClinicalTrials.gov

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

PEG-interferon alfa-2b

Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.

PROCEDURE

Conventional surgery

Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.

PROCEDURE

Neoadjuvant therapy

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00276523 - PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery | Biotech Hunter | Biotech Hunter